期刊文献+

组织芯片和常规制片检测乳腺癌相关癌基因产物的比较

Comparative Analysis on the Expression of Associated Genes Production in Breast Carcinoma by Tissue Microarray and by Traditional Pathological Investigation
暂未订购
导出
摘要 目的:探讨不同规格组织芯片在乳腺癌相关基因产物检测中的应用价值。方法:采用微波修复免疫组织化学SP法和组织芯片技术,检测ER、PR、nm23、Her2、p53在31例乳腺癌组织中的表达,并与常规病理学方法进行比较分析。结果:不同规格组织芯相比较,免疫组化结果几乎完全一致。常规制片免疫组化阴性,而组织芯片免疫组化阳性者包括ER2例、PR1例;常规制片免疫组化阳性,而组织芯片免疫组化阴性者包括nm23、Her2各1例。部分病例常规制片免疫组化和组织芯片免疫组化阳性表达强度略有不同。结论:组织芯片的免疫组化结果与常规制片免疫组化比较,经统计学处理,差异无显著性(P>0.05)。组织芯片技术有良好应用价值和广阔发展前景。 Objective To exploethe significance of each type of tissue microarrary on the examine of associated genes production in breast carcinoma. Methods Tissue microarray technology and immunohistoehemistry were used to detect the expression of ER,PR,nm23, Her-2 and p53 in 31 cases of breast carcinoma and compared theresult with the traditional pathological investigation. Results The difference was no found detween the immunohistochemistric result by 1.0 mm tissue microarray and by 0.5 mm tissue microarray. 2 cases of ER and 1 of PR were negative by traditional pathological technology,but were positive by tissue microarray. 1 case of nm23 and 1 of Her-2 were positive by traditional pathological technology,but were negative by tissue microarray. On the expressional strength of ER, PR, nm23, Her-2 and p53,the nigligible difference was found detween by traditional pathological technology and by tissue mieroarray in some cases. Conclusion On the positive rate of ER, PR, nm23, Her-2 and p53, the significant difference was no found detween the result with the traditional pathological investigation and with the tissue microarray(P〉0.05). It has important pracyieal significance and broad application prospect in pathology.
作者 姜辉 周晓秋
出处 《实用医技杂志》 2006年第10期1609-1610,共2页 Journal of Practical Medical Techniques
关键词 乳腺肿瘤 组织芯片 免疫组织化学 癌基因 Breast neoplasms Tissue microarray Immunohistochemistry Oneogene
  • 相关文献

参考文献6

二级参考文献32

  • 1Moch H Kononen T K allionemi OP et al Tissue microarrays what will they bring to lolecular abnd abatuomic pathology ?Adv Anat Patol 2001,8:14-20
  • 2Ekins R,Chu FW. Microarrays: their origins and applications. Trends Biotechnol, 1999, 17, 217-218.
  • 3Wooster R. Cancer classification with DNA microarrays is less more? Trends Genet, 2000, 16:327-329.
  • 4Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res,2000,60:6617-6622.
  • 5Richter J, Wagner U, Kononen J. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol, 2000,157:787-794.
  • 6Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. CancerRes, 2000,60:5340-5344.
  • 7Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res,1999, 59:803-806.
  • 8Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol,1999,154:981-986.
  • 9Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res,1999,5:1966-1975
  • 10Battfora H The multutumor (sausage)tissue block :novel method for immunohistochemical antibody testing Lab Inveat ,1986,55:244-248

共引文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部